Integra LifeSciences to Present at the Goldman Sachs Healthcare Conference

PLAINSBORO, N.J., Jun 8, 2001 (BUSINESS WIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) announced today that it is scheduled to present at the Goldman Sachs 22nd Annual Healthcare Conference in Dana Point, California on Wednesday, June 13, 2001 beginning at 7:40 PM EST.

The presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. Access to the live presentation is available through an audio webcast that can be accessed through the Calendar Events link in the Investor Relations section of Integra's website at www.integra-ls.com. The username and password information needed to access the webcast is provided on this page. Additionally, a replay of the webcast presentation will be available through June 20, 2001.

Mr. Essig's presentation will provide an overview of the Company's operating divisions, with a focus on currently marketed products and the product pipeline, recent financial history and the Company's overall business strategy for growth.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world.

The Company has approximately 550 permanent employees. Please visit the Company's website at www.integra-ls.com.

Statements made in the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions.

In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" in the recently filed registration statement on Form S-3 and in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation
www.integra-LS.com

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, 609/936-2481
jhenneman@integra-ls.com
or
John Bostjancic, 609/936-2239
jbostjancic@integra-ls.com